# Menarini Asia-Pacific and Pharmacosmos partner to bring first-in-class oncology supportive care therapy Cosela® to Asian patients

- Link: https://www.thailand-business-news.com/pr-news/menarini-asia-pacific-and-pharmacosmos-partner-to-bring-first-in-class-oncology-supportive-care-therapy-cosela-to-asian-patients
- Published: 2026-07-21T10:00:00+07:00
- Author: PR Newswire

|   |   |

SINGAPORE, July 21, 2026 /PRNewswire/ — Menarini Asia-Pacific today announced an
exclusive partnership with Pharmacosmos A/S to register, commercialise and distribute
Cosela^(®) (trilaciclib) across its Asia-Pacific markets.

Chemotherapy-induced myelosuppression (CIM) is a potentially debilitating side effect
that damages bone marrow, significantly impacting its hematopoietic function (or
its ability to produce healthy blood cells).  For patients with extensive-stage 
small cell lung cancer (ES-SCLC), chemotherapy remains a cornerstone of treatment,
yet it is a major dose limiting complication that can disrupt treatment and compromise
outcomes^([1]). Cosela^(®) is a first-in-class prophylactic therapy^([2]) FDA approved
to help protect bone marrow from CIM, addressing a significant unmet need in oncology
supportive care for these patients.

Under the agreement, Menarini Asia-Pacific will manage all aspects of registration,
reimbursement, commercialisation and distribution of Cosela^(®) in Australia, Hong
Kong/Macau, Indonesia, Malaysia, New Zealand, Philippines, Singapore, South Korea,
Taiwan, Thailand and Vietnam.

"Cosela^(®) represents an important advancement in oncology supportive care and 
the kind of innovation that can make a meaningful difference for patients," said**
Glen Godresse, Chief Executive Officer of Menarini Asia-Pacific**. "Partnerships
like this are central to Menarini Asia-Pacific’s mission of helping innovative therapies
reach patients with our end-to-end capabilities. We look forward to working with
Pharmacosmos to expand access to Cosela^(®) across our region and help more patients
benefit from this first-in-class treatment."

"As we looked to expand access to Cosela^(®) across Asia-Pacific, we wanted a long-
term partner with the capabilities to support every stage of the journey, from registration
through to commercialization and patient access," said **Klaus Abel, Vice President,
Global Commercial Partnerships, Pharmacosmos**. "Menarini Asia-Pacific’s deep local
market expertise and patient-focused approach make them the ideal partner to bring
this important innovation to patients across the region."

Cosela^(®) is currently marketed in the United States and China and is under registration
in Europe. Subject to regulatory approvals, the first Asia-Pacific launch is anticipated
in Hong Kong in 2028, followed by other markets thereafter.

The partnership builds on an existing relationship between the two companies, following
a 2024 agreement to commercialise innovative iron infusion Monofer^(®) across key
Asia-Pacific markets.

  |

**References**

  |  
 |

[1]. Weiss JM et al. _Managing Chemotherapy-Induced Myelosuppression with Trilaciclib. _Clin Lung Cancer. 2021. Available at: [https://pubmed.ncbi.nlm.nih.gov/33895103/](https://pubmed.ncbi.nlm.nih.gov/33895103/)

  |  
 |

[2]. Alqahtani S, Alzahrani A, Alhakamy NA, et al. _Trilaciclib: a first-in-class CDK4/6 inhibitor with dual roles in myelopreservation and cell cycle regulation._ Medicinal Chemistry Research. 2024. Available at: [https://link.springer.com/article/10.1007/s00044-024-03288-y](https://link.springer.com/article/10.1007/s00044-024-03288-y) 

  |

_This press release is intended for media and investor relations purposes only and
does not constitute medical advice, product promotion or a recommendation for the
use of any medicinal product. Cosela^(®) (trilaciclib) is subject to local regulatory
approvals._

**About Menarini Asia-PacificMenarini Asia-Pacific is a member of the Menarini Group,
a leading international pharmaceutical and diagnostic company with a heritage of
over 135 years and over 17,000 employees in 140 countries. Here in Asia-Pacific,
Menarini’s vision is to be a leading provider of important healthcare brands to 
improve the lives of people. Menarini Asia-Pacific operates across the entire commercial
value chain, from clinical development, regulatory approval, and product launch 
to lifecycle management with a diverse portfolio of proprietary and partnered brands
in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory,
Gastroenterology, Cardio-metabolic, Oncology/Specialty Care and Men’s Health. 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Menarini Asia-Pacific and Pharmacosmos partner to bring first-in-class oncology supportive care therapy Cosela® to Asian patients ](http://www.prnasia.com/story/archive/5007811_AE07811_0?rand=184833)